| scholarly article | Q13442814 |
| P2093 | author name string | E Antonio Chiocca | |
| Behnam Badie | |||
| David S Baskin | |||
| Bin S Teh | |||
| Herbert B Newton | |||
| John C Grecula | |||
| Robert Cavaliere | |||
| Simon S Lo | |||
| Estuardo Aguilar-Cordova | |||
| Laura K Aguilar | |||
| John M McGregor | |||
| Jana Portnow | |||
| Lee A Wheeler | |||
| Todd W Trask | |||
| Andrea G Manzanera | |||
| Pamela Z New | |||
| Susan D Bell | |||
| P2860 | cites work | Systemic gene therapy of murine melanoma using tissue specific expression of the HSVtk gene involves an immune component. | Q45871117 |
| Generation of an anti-tumour immune response in a non-immunogenic tumour: HSVtk killing in vivo stimulates a mononuclear cell infiltrate and a Th1-like profile of intratumoural cytokine expression | Q45881664 | ||
| Vaccination elicits correlated immune and clinical responses in glioblastoma multiforme patients | Q46180952 | ||
| The Functional Assessment of Cancer Therapy (FACT) scale. Development of a brain subscale and revalidation of the general version (FACT-G) in patients with primary brain tumors | Q52880557 | ||
| Phase I study of adenoviral delivery of the HSV-tk gene and ganciclovir administration in patients with current malignant brain tumors. | Q54635100 | ||
| Improved Endpoints for Cancer Immunotherapy Trials | Q24603112 | ||
| Immunotherapy advances for glioblastoma | Q26866513 | ||
| Immunotherapy for primary brain tumors: no longer a matter of privilege | Q27002510 | ||
| A phase II, multicenter trial of rindopepimut (CDX-110) in newly diagnosed glioblastoma: the ACT III study | Q27853118 | ||
| The blockade of immune checkpoints in cancer immunotherapy | Q27860852 | ||
| Improved Survival with Ipilimumab in Patients with Metastatic Melanoma | Q27861062 | ||
| A New Design for Randomized Clinical Trials | Q28239541 | ||
| Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial | Q29547224 | ||
| Malignant gliomas in adults | Q29615708 | ||
| Nivolumab and ipilimumab versus ipilimumab in untreated melanoma | Q29620657 | ||
| Pembrolizumab for the treatment of non-small-cell lung cancer | Q29620851 | ||
| PD-1 blockade induces responses by inhibiting adaptive immune resistance | Q29620856 | ||
| Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer | Q29620913 | ||
| Residual tumor volume versus extent of resection: predictors of survival after surgery for glioblastoma | Q30847783 | ||
| Phase IB Study of Gene-Mediated Cytotoxic Immunotherapy Adjuvant to Up-Front Surgery and Intensive Timing Radiation for Malignant Glioma | Q34208293 | ||
| Chemotherapy Delivered After Viral Immunogene Therapy Augments Antitumor Efficacy Via Multiple Immune-mediated Mechanisms | Q34343736 | ||
| Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma | Q34478015 | ||
| Immunologic Escape After Prolonged Progression-Free Survival With Epidermal Growth Factor Receptor Variant III Peptide Vaccination in Patients With Newly Diagnosed Glioblastoma | Q34488771 | ||
| Neoadjuvant in situ gene-mediated cytotoxic immunotherapy improves postoperative outcomes in novel syngeneic esophageal carcinoma models | Q35549847 | ||
| Cytoreduction surgery reduces systemic myeloid suppressor cell populations and restores intratumoral immunotherapy effectiveness | Q36161355 | ||
| Immunological responses in a patient with glioblastoma multiforme treated with sequential courses of temozolomide and immunotherapy: case study | Q37011021 | ||
| Analysis of overall survival in patients with nonmetastatic castration-resistant prostate cancer treated with vaccine, nilutamide, and combination therapy | Q37193043 | ||
| Systemic effects of local radiotherapy | Q37539309 | ||
| Cytotoxic immunotherapy strategies for cancer: Mechanisms and clinical development | Q37861631 | ||
| The Spectrum of Vaccine Therapies for Patients With Glioblastoma Multiforme | Q38035788 | ||
| Oncolytic viruses and their application to cancer immunotherapy | Q38207011 | ||
| The combination of adenoviral HSV TK gene therapy and radiation is effective in athymic mouse glioblastoma xenografts without increasing toxic side effects. | Q40568783 | ||
| Adenovirus-mediated herpes simplex virus thymidine kinase gene and ganciclovir therapy leads to systemic activity against spontaneous and induced metastasis in an orthotopic mouse model of prostate cancer | Q41133838 | ||
| Prodrug-activated gene therapy: involvement of an immunological component in the "bystander effect". | Q41221700 | ||
| Myeloid-derived suppressor cell accumulation and function in patients with newly diagnosed glioblastoma | Q41773542 | ||
| Gene-mediated cytotoxic immunotherapy as adjuvant to surgery or chemoradiation for pancreatic adenocarcinoma | Q42153454 | ||
| Adenovirus-mediated gene therapy with sitimagene ceradenovec followed by intravenous ganciclovir for patients with operable high-grade glioma (ASPECT): a randomised, open-label, phase 3 trial | Q42284125 | ||
| Gross total but not incomplete resection of glioblastoma prolongs survival in the era of radiochemotherapy | Q42623558 | ||
| Immune-dependent distant bystander effect after adenovirus-mediated suicide gene transfer in a rat model of liver colorectal metastasis | Q43550584 | ||
| In vivo surgical resection plus adjuvant gene therapy in the treatment of mammary and prostate cancer | Q43586830 | ||
| Enhanced therapeutic effect of HSV-tk+GCV gene therapy and ionizing radiation for prostate cancer | Q43586837 | ||
| Temozolomide enhances herpes simplex virus thymidine kinase/ganciclovir therapy of malignant glioma. | Q43761368 | ||
| Cancer gene therapy with HSV-tk/GCV system depends on T-cell-mediated immune responses and causes apoptotic death of tumor cells in vivo | Q43803202 | ||
| Response criteria for phase II studies of supratentorial malignant glioma | Q44781447 | ||
| Impact of preimmunization on adenoviral vector expression and toxicity in a subcutaneous mouse cancer model | Q45854903 | ||
| Adenovirus-mediated gene therapy of experimental gliomas | Q45870226 | ||
| P433 | issue | 8 | |
| P921 | main subject | cytotoxicity | Q246181 |
| immunotherapy | Q1427096 | ||
| multicenter clinical trial | Q6934595 | ||
| P304 | page(s) | 1137-1145 | |
| P577 | publication date | 2016-02-02 | |
| P1433 | published in | Neuro-Oncology | Q15724471 |
| P1476 | title | Phase II multicenter study of gene-mediated cytotoxic immunotherapy as adjuvant to surgical resection for newly diagnosed malignant glioma | |
| P478 | volume | 18 |
| Q97532176 | Altering the response to radiation: radiosensitizers and targeted therapies in pancreatic ductal adenocarcinoma: preclinical and emerging clinical evidence |
| Q58797848 | Comparative effect of immunotherapy and standard therapy in patients with high grade glioma: a meta-analysis of published clinical trials |
| Q47878958 | Current and emerging EGFR therapies for glioblastoma. |
| Q55457323 | Current state of immunotherapy for glioblastoma. |
| Q102063578 | Effects of oncolytic viruses and viral vectors on immunity in glioblastoma |
| Q40060078 | Gene Delivery in Neuro-Oncology |
| Q91734216 | Gene Therapy for Neurologic Disease: A Neurosurgical Review |
| Q33733266 | Icariside II induces cell cycle arrest and apoptosis in human glioblastoma cells through suppressing Akt activation and potentiating FOXO3a activity |
| Q38947116 | Immunological effects of chemotherapy and radiotherapy against brain tumors |
| Q45875535 | Immunotherapy and gene therapy as novel treatments for cancer |
| Q57475700 | Immunotherapy for Brain Tumors |
| Q64997060 | Immunotherapy for glioblastoma: going viral. |
| Q52353493 | Local Immunotherapy of Cancer: Innovative Approaches to Harnessing Tumor-Specific Immune Responses. |
| Q47215596 | Modeling tumor immunity of mouse glioblastoma by exhausted CD8+ T cells |
| Q101450383 | Neoadjuvant Gene Mediated Cytotoxic Immunotherapy for Non-Small Cell Lung Cancer - Safety and Immunologic Activity |
| Q38749871 | Oncolytic Virotherapy for the Treatment of Malignant Glioma |
| Q52650848 | Phase I Study of Intrapleural Gene-Mediated Cytotoxic Immunotherapy in Patients with Malignant Pleural Effusion |
| Q92443672 | Phase I study of gene-mediated cytotoxic immunotherapy with AdV-tk as adjuvant to surgery and radiation for pediatric malignant glioma and recurrent ependymoma |
| Q59333218 | Potential Epigenetic-Based Therapeutic Targets for Glioma |
| Q47827127 | Preclinical investigation of combined gene-mediated cytotoxic immunotherapy and immune checkpoint blockade in glioblastoma |
| Q97543045 | Suicide gene therapy for the treatment of high-grade glioma: past lessons, present trends, and future prospects |
| Q96829832 | The History of Neurosurgery at Houston Methodist Hospital |
| Q92029579 | The cell-based approach in neurosurgery: ongoing trends and future perspectives |
| Q92247838 | The new kid on the block: suicide gene therapy to modulate cancer immunosurveillance for children with high-risk malignant brain tumors |
| Q61815503 | Vectors for Glioblastoma Gene Therapy: Viral & Non-Viral Delivery Strategies |
| Q57804908 | Viral and other therapies for recurrent GBM: is a 24-month durable response unusual? |
| Q59355755 | Viruses in cancer therapy - from benchwarmers to quarterbacks |
Search more.